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Abstract: Tumor invasion and metastasis involve processes in which actin cytoskeleton
rearrangement induced by Fascin1 plays a crucial role. Indeed, Fascin1 has been
found overexpressed in tumors with worse prognosis. Migrastatin and its analogues
target Fascin1 and inhibit its activity. However, there is need for novel and smaller
Fascin1 inhibitors. The aim of this study was to assess the effect of compound G2 in
colorectal cancer cell lines and compare it to migrastatin in  in vitro  and  in vivo
assays. Molecular modeling, actin bundling, cell viability, inmunofluorescence,
migration and invasion assays were carried out in order to test anti-migratory and anti-
invasive properties of compound G2. In addition, the  in vivo  effect of compound G2
was evaluated in a zebrafish model of invasion. HCT-116 cells exhibited the highest
Fascin1 expression from eight tested colorectal cancer cell lines. Compound G2
showed important inhibitory effects on actin bundling, filopodia formation, migration
and invasion in different cell lines. Moreover, compound G2 treatment resulted in
significant reduction of invasion of DLD-1 overexpressing Fascin1 and HCT-116 in
zebrafish larvae xenografts; this effect being less evident in Fascin1 known-down HCT-
116 cells. This study proves, for the first time, the  in vitro  and  in vivo  antitumoral
activity of compound G2 on colorectal cancer cells and guides to design improved
compound G2-based Fascin1 inhibitors.
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Response to Reviewers: General remarks:
Careful proofreading is necessary.
REPLY: The manuscript has been now reviewed carefully by a native English speaker.
It is required to use the same cell lines for each assay: HCT-116 control + HCT-116
fascin siRNA and DLD1 control + fascin overexpression.
REPLY: We understand the referee’s comment and we have now performed the
corresponding experiments accordingly.  All of them are now included in the new
version of the manuscript (main text and supplemental material).
We are now describing to the referee the main issues about the above assays with
transfected cells.
Figure 2. This is not new but has been already shown by Huang et al., 2015. The
evaluation method to analyze the effect of the compounds on fascin is not clear and it
is not possible to read the graph labeling.
REPLY: Huang et al. (2018) performed elegant experiments to identify small molecules
that specifically block filopodia formation, cell migration and invasion. Compound G2
was among these molecules. They appropriately used fluorescence microscopy (63x
magnification) together with isothermal titration calorimetry to test the biochemical
mechanism by which G2 inhibits fascin1. Nonetheless, transmission electronic
microscopy (TEM) (135,000x magnification), as we presented here, was not used in
the referred paper.
Moreover, we have now modified the graph labelling in Figure 2.
Huang, J., Dey, R., Wang, Y., Jakoncic, J., Kurinov, I., & Huang, X. Y. (2018).
Structural Insights into the Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor.
J Mol Biol, 430(9), 1324-1335. doi:10.1016/j.jmb.2018.03.009
Figure 3: Only HCT-116 cells were analyzed the other cell lines are missing, see
"general remarks"
REPLY: Not all cell lines are suitable to assess filopodia formation. In order to provide
an extra cell line to demonstrate the effect of compound G2, HaCaT human cells were
used. HaCaT are spontaneously immortalized human keratinocyte cells expressing
high levels of fascin1 (https://www.proteinatlas.org/ENSG00000075618-FSCN1/cell).
As it is shown in the following figure (for reviewer only), lamellipodia formation in the
presence of compound G2 was clearly abolished in HaCat cells, confirming once more
the implication of the drug in the lamellipodia formation.
Figure for review only: Representative images of immunofluorescence assaysof HaCat
cells for fascin1 (green), nucleus (blue) and actin (red) are shown. A) Control condition
(DMSO); B) 10 ng/mL Epidermal Growth Factor (EGF, migration stimulator); C) 50 µM
PD98059 (Mek inhibitor); D) 100 µM migrastatin; E) 10 µM compound G2. Cells were
fixed with bouin and co-stained with anti-Fascin1 antibody (1/250) and Hoechst-33258.
For actin staining, cells were fixed with methanol and stained with anti-actin antibody
(1/1000) and Hoechst-33258. Images were captured with a LSM 510 META confocal
fluorescence microscope with 63X oil objective.
RESULTS (PAGE 14): “Similar results were observed with an extra cell line expressing
Fascin1 (HaCat) as DLD1 morphology was not suitable for assessing lamellipodium
formation (data not shown)”.
Additionally, we now include the immunofluorescence assay with genetically knocked-
down HCT-116 for fascin1 (Supplementary material S5). The resulting experiment
shows that lamellipodia formation is clearly compromised in fascin1 silenced cells and
therefore, the effect of G2 cannot be exerted in an additive fashion. Nonetheless, it is
important to notice that 100% transfection efficiency was not achieved and thus, some
cells are stained in green and still display lamellipodia.
When pharmacological inhibition (compound G2) is added to knocked-down cells,
lamellipodia are also abolished. The following figure includes the effect of compound
G2 on silenced cells. Nonetheless, in the supplementary material we have only added
columns A-D because the lamellipodia formation in silenced cells was already
abolished without the drug.
Figure for review only: Representative images of immunofluorescence assays for
fascin1 (green), nucleus (blue) and actin (red) are shown. A) Control condition (DMSO)
with siRNA-A transfected HCT-116 cells; B) Control condition (DMSO) with fascin1
silenced HCT-116 cells; C) Fascin1 silenced HCT-116 cells with 10 ng/mL Epidermal
Growth Factor (EGF, migration stimulator), D) Fascin1 silenced HCT-116 cells with 50
µM PD98059 (Mek inhibitor); E) Fascin1 silenced HCT-116 cells with 20 µM compound
G2. Colorectal carcinoma HCT-116 cells were genetically knocked-down for Fascin1
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with short interfering siRNA, control HCT-116 was transfected with siRNA-A (MOCK).
Cells were fixed with bouin and co-stained with anti-Fascin1 antibody (1/250) and
Hoechst-33258. For actin staining, cells were fixed with methanol and stained with anti-
actin antibody (1/1000). Images were captured with a LSM 510 META confocal
fluorescence microscope with 63X oil objective.
Figure 4: The siRNA and overexpressing approaches are missing. Figure 5: Only HCT-
116 cells were analyzed the other cell lines are missing, see "general remarks"
REPLY: As suggested by the referee, a new supplemental figure (S9) has been
included presenting new migration and invasion assays using HCT-116 control + HCT-
116 fascin1 siRNA and DLD1 control + fascin1 overexpression. In this way, genetic
and pharmacological inhibitions could be analyzed in vitro.
Figure for review only: Scratch of transfected DLD-1 cells with pGFP-Fsc1.
Fascin1 silenced HCT-116 cells lead to a slightly decrease in migration and invasion
compared to MOCK HCT-116 cells, being more significant in the presence of
compound G2. Similarly, DLD1 overexpressing Fascin1 migrate and invade
significantly more than MOCK DLD-1 cells whilst treated DLD1 cells display reduced
capacities.
Supplementary material S9. Inhibition of the migration and invasive capacities exerted
by compound G2 on transfected cells Colorectal carcinoma HCT-116 cells were
genetically knocked-down for Fascin1 with short interfering siRNA, MOCK control HCT-
116 was transfected with siRNA-A: A) Percentage of migration. B) Percentage of
invasion. Colorectal carcinoma DLD-1 cells were genetically overexpressed for
Fascin1 with Fascin1-GFP vector, MOCK control DLD-1 was transfected with pGFP N3
control vector: C) Percentage of migration. D) Percentage of invasion Data are
representative of two similar experiments Error bars, mean ± SD of duplicates. *
p<0.05, ** p<0.01 compared to MOCK condition; n.s: non-significant.
Figure 6: "Good correlation was observed between Fascin1 expression and cell
invasion". This is not true HCT-15 cells exhibit higher fascin mRNA levels than DLD1
cells and there is not difference between these cell lines.
REPLY: The reviewer´s comment is pertinent. This statement can be applied for most
but not all cell lines assayed. Therefore, the sentence has been reworded as follows:
RESULTS (PAGE 18): “Good correlation was observed between Fascin1 expression
and cell invasion for all cell lines assayed except HCT-15 whose invasion was lower
than expected possibly due to other fascin1 independent factors affecting invasion
(Figure 6B). Therefore, and because of good correlation, HCT-116 was selected for
being the cell line with the highest and DLD-1 for its lower Fascin1 expression and cell
invasion.”
Figure 7: These experiments have been properly done. However, there are still some
concerns. Figure 7C. There is no significant (n.s.) difference between siRNA control
cells treated with 5 or 10 µM G2. Why is the dose-dependency missing in Fascin-
expressing cells?  The same is true for Figure 7F, in fascin expressing cells one would
expect a dose-dependency.
REPLY: We understand the reviewer´s concerns about the dose-dependency
relationship in transfected cells. Migration and invasion are complex processes
involving other proteins and factors apart from fascin1. The invasion capacity cannot
be only associated with fascin1 levels.
The expression of fascin1 in silenced HCT-116 cells was low and with such low levels,
it was difficult to find a clear dose-dependent relationship of an inhibitory compound
(although a trend was shown). Nevertheless, the demonstration that the effect of G2 is
fascin1 dependent comes from the comparison between siRNA fascin1 HCT-116 and
Fascin1 transfected DLD1 (Fig 7C and 7F) where the inhibitory effect of G2 on invasion
is maximum when fascin1 is overexpressed and minimum when it is silenced.
Accordingly, this inhibitory effect is intermediate when fascin1 expression is not altered
by transfection. It is clear that close concentrations (i.e. 5 and 10uM) can result in non-
significant relationship although the tendency is visible by comparing the bar heights.
Although a significant effect compared to MOCK conditions was found, the absence of
this tendency in Fascin1 transfected DLD1 (Fig. 7F) could be explained by the fact that
the G2 inhibitory activity is in its maximum (regardless 5 or 10 uM G2) because under
this circumstance, invasion is more dependent on Fascin1 (which is exogenously
overexpressed) compared to the non-transfected condition that is closer to the in vivo
condition. Nonetheless, there is a common anti-invasive phenotype when either
pharmacological or genetic inhibition are performed in HCT-116 cells. Huang et al
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(2018) firstly described this fascin1 inhibitory effect to be specific.
Using high-throughput screening, Huang et al.  identified and characterized small
molecules that inhibit the actin-bundling activity of fascin. Focusing on one G2 and
breast cancer cells, they demonstrated that it specifically blocks filopodial formation,
migration and invasion in vitro, and metastasis in vivo (Nat Commun. 2015 Jun
17;6:7465). Another proof suggesting a direct effect of G2 on fascin1 was the recently
published X-ray structure of G2 binding fascin1 published by the same group (J Mol
Biol. 2018 Apr 27;430(9):1324-1335) and cited in the manuscript. Despite these
findings including ours we cannot exclude additional off-target effects of G2. For this
reason, we have included the following sentence in the discussion.
DISCUSSION (PAGE 21): “However and despite these evidences, additional off-target
anti-tumoral effects of G2 apart from Fascin1 are also possible”.
Huang, J., Dey, R., Wang, Y., Jakoncic, J., Kurinov, I., & Huang, X. Y. (2018).
Structural Insights into the Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor.
J Mol Biol, 430(9), 1324-1335. doi:10.1016/j.jmb.2018.03.009
Huang J, Dey R, Wang Y, Jakoncic J, Kurinov I, Huang XY. Structural Insights into the
Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor. J Mol Biol. 2018 Apr
27;430(9):1324-1335. doi: 10.1016/j.jmb.2018.03.009.
Overall important experiments are still missing and often the interpretation of the
results is wrong. In addition, the writing of the MS has to be improved.
I recommend to only accept the manuscript for publication if all experiments were
performed (see above) and, more importantly, when the results were correctly
interpreted.
REPLY: All important experiments assessing migration and invasion have now been
performed using the two cell lines with Fascin1 overexpressed and silenced when
appropriate. The evidence reporting now here demonstrated an inhibitory effect of G2
compound on actin bundling and cell migration and invasion, these last effect being
more evident in Fascin1 overexpressing than Fascin1 knock-down tumor cells thus
suggesting a direct effect of G2 on Fascin1 although additional off-target effects cannot
be excluded. An extensive review by a native English speaker has been carried out to
improve the manuscript quality and understanding.
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Careful proofreading is necessary. 
REPLY: The manuscript has been now reviewed carefully by a native English speaker. 
It is required to use the same cell lines for each assay: HCT-116 control + HCT-116 fascin siRNA 
and DLD1 control + fascin overexpression. 
REPLY: We understand the referee’s comment and we have now performed the corresponding 
experiments accordingly.  All of them are now included in the new version of the manuscript 
(main text and supplemental material). 
We are now describing to the referee the main issues about the above assays with transfected 
cells. 
Figure 2. This is not new but has been already shown by Huang et al., 2015. The evaluation 
method to analyze the effect of the compounds on fascin is not clear and it is not possible to 
read the graph labeling. 
REPLY: Huang et al. (2018) performed elegant experiments to identify small molecules that 
specifically block filopodia formation, cell migration and invasion. Compound G2 was among 
these molecules. They appropriately used fluorescence microscopy (63x magnification) 
together with isothermal titration calorimetry to test the biochemical mechanism by which G2 
inhibits fascin1. Nonetheless, transmission electronic microscopy (TEM) (135,000x 
magnification), as we presented here, was not used in the referred paper. 
Moreover, we have now modified the graph labelling in Figure 2. 
Huang, J., Dey, R., Wang, Y., Jakoncic, J., Kurinov, I., & Huang, X. Y. (2018). Structural Insights into the Induced-fit 
Inhibition of Fascin by a Small-Molecule Inhibitor. J Mol Biol, 430(9), 1324-1335. doi:10.1016/j.jmb.2018.03.009 
Figure 3: Only HCT-116 cells were analyzed the other cell lines are missing, see "general 
remarks" 
REPLY: Not all cell lines are suitable to assess filopodia formation. In order to provide an extra 
cell line to demonstrate the effect of compound G2, HaCaT human cells were used. HaCaT are 
spontaneously immortalized human keratinocyte cells expressing high levels of fascin1 
(https://www.proteinatlas.org/ENSG00000075618-FSCN1/cell). As it is shown in the following 
figure (for reviewer only), lamellipodia formation in the presence of compound G2 was clearly 
abolished in HaCat cells, confirming once more the implication of the drug in the lamellipodia 
formation. 
Rebuttal Click here to access/download;Authors' Response to
Reviewers' Comments;Montoro el al-Rebuttal to referee
 
Figure for review only: Representative images of immunofluorescence assaysof HaCat cells for 
fascin1 (green), nucleus (blue) and actin (red) are shown. A) Control condition (DMSO); B) 10 
ng/mL Epidermal Growth Factor (EGF, migration stimulator); C) 50 µM PD98059 (Mek 
inhibitor); D) 100 µM migrastatin; E) 10 µM compound G2. Cells were fixed with bouin and co-
stained with anti-Fascin1 antibody (1/250) and Hoechst-33258. For actin staining, cells were 
fixed with methanol and stained with anti-actin antibody (1/1000) and Hoechst-33258. Images 
were captured with a LSM 510 META confocal fluorescence microscope with 63X oil objective. 
RESULTS (PAGE 14): “Similar results were observed with an extra cell line expressing Fascin1 
(HaCat) as DLD1 morphology was not suitable for assessing lamellipodium formation (data not 
shown)”.   
Additionally, we now include the immunofluorescence assay with genetically knocked-down 
HCT-116 for fascin1 (Supplementary material S5). The resulting experiment shows that 
lamellipodia formation is clearly compromised in fascin1 silenced cells and therefore, the 
effect of G2 cannot be exerted in an additive fashion. Nonetheless, it is important to notice 
that 100% transfection efficiency was not achieved and thus, some cells are stained in green 
and still display lamellipodia.  
When pharmacological inhibition (compound G2) is added to knocked-down cells, lamellipodia 
are also abolished. The following figure includes the effect of compound G2 on silenced cells. 
Nonetheless, in the supplementary material we have only added columns A-D because the 
lamellipodia formation in silenced cells was already abolished without the drug. 
 
Figure for review only: Representative images of immunofluorescence assays for fascin1 
(green), nucleus (blue) and actin (red) are shown. A) Control condition (DMSO) with siRNA-A 
transfected HCT-116 cells; B) Control condition (DMSO) with fascin1 silenced HCT-116 cells; C) 
Fascin1 silenced HCT-116 cells with 10 ng/mL Epidermal Growth Factor (EGF, migration 
stimulator), D) Fascin1 silenced HCT-116 cells with 50 µM PD98059 (Mek inhibitor); E) Fascin1 
silenced HCT-116 cells with 20 µM compound G2. Colorectal carcinoma HCT-116 cells were 
genetically knocked-down for Fascin1 with short interfering siRNA, control HCT-116 was 
transfected with siRNA-A (MOCK). Cells were fixed with bouin and co-stained with anti-Fascin1 
antibody (1/250) and Hoechst-33258. For actin staining, cells were fixed with methanol and 
stained with anti-actin antibody (1/1000). Images were captured with a LSM 510 META 
confocal fluorescence microscope with 63X oil objective. 
Figure 4: The siRNA and overexpressing approaches are missing. Figure 5: Only HCT-116 cells 
were analyzed the other cell lines are missing, see "general remarks" 
REPLY: As suggested by the referee, a new supplemental figure (S9) has been included 
presenting new migration and invasion assays using HCT-116 control + HCT-116 fascin1 siRNA 
and DLD1 control + fascin1 overexpression. In this way, genetic and pharmacological 
inhibitions could be analyzed in vitro. 
 
Figure for review only: Scratch of transfected DLD-1 cells with pGFP-Fsc1. 
Fascin1 silenced HCT-116 cells lead to a slightly decrease in migration and invasion compared 
to MOCK HCT-116 cells, being more significant in the presence of compound G2. Similarly, 
DLD1 overexpressing Fascin1 migrate and invade significantly more than MOCK DLD-1 cells 
whilst treated DLD1 cells display reduced capacities.  
 
Supplementary material S9. Inhibition of the migration and invasive capacities exerted by 
compound G2 on transfected cells Colorectal carcinoma HCT-116 cells were genetically 
knocked-down for Fascin1 with short interfering siRNA, MOCK control HCT-116 was 
transfected with siRNA-A: A) Percentage of migration. B) Percentage of invasion. Colorectal 
carcinoma DLD-1 cells were genetically overexpressed for Fascin1 with Fascin1-GFP vector, 
MOCK control DLD-1 was transfected with pGFP N3 control vector: C) Percentage of migration. 
D) Percentage of invasion Data are representative of two similar experiments Error bars, mean 
± SD of duplicates. * p<0.05, ** p<0.01 compared to MOCK condition; n.s: non-significant. 
Figure 6: "Good correlation was observed between Fascin1 expression and cell invasion". This 
is not true HCT-15 cells exhibit higher fascin mRNA levels than DLD1 cells and there is not 
difference between these cell lines. 
REPLY: The reviewer´s comment is pertinent. This statement can be applied for most but not 
all cell lines assayed. Therefore, the sentence has been reworded as follows:  
RESULTS (PAGE 18): “Good correlation was observed between Fascin1 expression and cell 
invasion for all cell lines assayed except HCT-15 whose invasion was lower than expected 
possibly due to other fascin1 independent factors affecting invasion (Figure 6B). Therefore, 
and because of good correlation, HCT-116 was selected for being the cell line with the highest 
and DLD-1 for its lower Fascin1 expression and cell invasion.” 
Figure 7: These experiments have been properly done. However, there are still some concerns. 
Figure 7C. There is no significant (n.s.) difference between siRNA control cells treated with 5 or 
10 µM G2. Why is the dose-dependency missing in Fascin-expressing cells?  The same is true 
for Figure 7F, in fascin expressing cells one would expect a dose-dependency. 
REPLY: We understand the reviewer´s concerns about the dose-dependency relationship in 
transfected cells. Migration and invasion are complex processes involving other proteins and 
factors apart from fascin1. The invasion capacity cannot be only associated with fascin1 levels.  
The expression of fascin1 in silenced HCT-116 cells was low and with such low levels, it was 
difficult to find a clear dose-dependent relationship of an inhibitory compound (although a 
trend was shown). Nevertheless, the demonstration that the effect of G2 is fascin1 dependent 
comes from the comparison between siRNA fascin1 HCT-116 and Fascin1 transfected DLD1 (Fig 
7C and 7F) where the inhibitory effect of G2 on invasion is maximum when fascin1 is 
overexpressed and minimum when it is silenced. Accordingly, this inhibitory effect is 
intermediate when fascin1 expression is not altered by transfection. It is clear that close 
concentrations (i.e. 5 and 10uM) can result in non-significant relationship although the 
tendency is visible by comparing the bar heights. Although a significant effect compared to 
MOCK conditions was found, the absence of this tendency in Fascin1 transfected DLD1 (Fig. 7F) 
could be explained by the fact that the G2 inhibitory activity is in its maximum (regardless 5 or 
10 uM G2) because under this circumstance, invasion is more dependent on Fascin1 (which is 
exogenously overexpressed) compared to the non-transfected condition that is closer to the in 
vivo condition. Nonetheless, there is a common anti-invasive phenotype when either 
pharmacological or genetic inhibition are performed in HCT-116 cells. Huang et al (2018) firstly 
described this fascin1 inhibitory effect to be specific.  
Using high-throughput screening, Huang et al.  identified and characterized small molecules 
that inhibit the actin-bundling activity of fascin. Focusing on one G2 and breast cancer cells, 
they demonstrated that it specifically blocks filopodial formation, migration and invasion in 
vitro, and metastasis in vivo (Nat Commun. 2015 Jun 17;6:7465). Another proof suggesting a 
direct effect of G2 on fascin1 was the recently published X-ray structure of G2 binding fascin1 
published by the same group (J Mol Biol. 2018 Apr 27;430(9):1324-1335) and cited in the 
manuscript. Despite these findings including ours we cannot exclude additional off-target 
effects of G2. For this reason, we have included the following sentence in the discussion. 
DISCUSSION (PAGE 21): “However and despite these evidences, additional off-target anti-
tumoral effects of G2 apart from Fascin1 are also possible”. 
Huang, J., Dey, R., Wang, Y., Jakoncic, J., Kurinov, I., & Huang, X. Y. (2018). Structural Insights into the Induced-fit 
Inhibition of Fascin by a Small-Molecule Inhibitor. J Mol Biol, 430(9), 1324-1335. doi:10.1016/j.jmb.2018.03.009 
Huang J, Dey R, Wang Y, Jakoncic J, Kurinov I, Huang XY. Structural Insights into the Induced-fit Inhibition of Fascin 
by a Small-Molecule Inhibitor. J Mol Biol. 2018 Apr 27;430(9):1324-1335. doi: 10.1016/j.jmb.2018.03.009.  
 
Overall important experiments are still missing and often the interpretation of the results is 
wrong. In addition, the writing of the MS has to be improved. 
I recommend to only accept the manuscript for publication if all experiments were performed 
(see above) and, more importantly, when the results were correctly interpreted. 
 
REPLY: All important experiments assessing migration and invasion have now been performed 
using the two cell lines with Fascin1 overexpressed and silenced when appropriate. The 
evidence reporting now here demonstrated an inhibitory effect of G2 compound on actin 
bundling and cell migration and invasion, these last effect being more evident in Fascin1 
overexpressing than Fascin1 knock-down tumor cells thus suggesting a direct effect of G2 on 
Fascin1 although additional off-target effects cannot be excluded. An extensive review by a 
native English speaker has been carried out to improve the manuscript quality and 
understanding. 
                                                                                                  
  
 
C/ Mezquita s/n, Paraje los Arcos 




       Cartagena, December the 5th 2019 
Dear Editor, 
Please find enclosed the revised version of our work: “Novel anti-migratory and anti-
invasive properties of a Fascin1 inhibitor on colorectal cancer cells”  
In the current version of the manuscript, we have given point-by-point response to all 
reviewer´s questions for which we have performed new assays requested by the 
reviewer in his second revision. These new experiments includes, when appropriate, 
silencing and overexpression of fascin1 in HCT-116 and DLD1 cell lines, respectively in 
order to assess the effect of G2 compound on migration and invasion of tumor cells 
both in vitro and in vivo. Besides, we show that G2 disrupts the fascin-actin filament 
interactions (transmission electron microscopy) and cellular lamelipodia formation 
(confocal microscopy) in colorectal cancer cells. Text changes from the first revision are 
highlighted in yellow and from the second revision in light blue. 
During more than eight years our group have been characterizing the molecular 
features of serrated pathway of the colorectum and found out that Fascin1 was an 
interesting molecular target. This study reports for the first time that a Fascin1 inhibitor 
has anti-migratory and anti-invasive properties in colorectal cancer cells even at lower 
concentrations than migrastatin, one the most characterized Fascin1 inhibitor. Using 
this strategy, we have here confirmed a novel class of compounds that can be a 
foundation for treating cancer characterized by fascin1 overexpression such as Serrated 
Adenocarcinoma of the colorectum. The study provides significant evidence that G2 
compound is an interesting candidate for further investigation/chemical modifications to 
develop new Fascin1-specific therapies for colorectal cancer and constitutes the first 
rationale for a tailored therapy in serrated adenocarcinoma.  
Cover Letter
                                                                                                  
  
 
C/ Mezquita s/n, Paraje los Arcos 




All authors have contributed to and agreed on the content of the manuscript, and the 
respective roles of each author. The manuscript is original and has not been published 
previously, in any language, in whole or in part, and is not currently under 
consideration elsewhere. The study was approved by the Hospital Ethics Committee and 
was carried out in accordance with the ethical standards laid down in the 1964 
Declaration of Helsinki and its later amendments.  
Your comments and suggestions will be greatly appreciated. 
Yours faithfully. 
 
Pablo Conesa Zamora, PharmD. 
Key messages 
 
-Fascin is crucial for tumor invasion and metastasis and is overexpressed in bad 
prognostic tumors 
-Several adverse tumors overexpress Fascin1 and lack targeted therapy 
-Anti-fascin G2 is for the first time evaluated in colorectal carcinoma and compared 
with migrastatin 
-Filopodia formation, migration activity and invasion in vitro and in vivo assays were 
performed 
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Tumor invasion and metastasis involve processes in which actin cytoskeleton 
rearrangement induced by Fascin1 plays a crucial role. Indeed, Fascin1 has been found 
overexpressed in tumors with worse prognosis. Migrastatin and its analogues target 
Fascin1 and inhibit its activity. However, there is need for novel and smaller Fascin1 
inhibitors. The aim of this study was to assess the effect of compound G2 in colorectal 
cancer cell lines and compare it to migrastatin in in vitro and in vivo assays. Molecular 
modeling, actin bundling, cell viability, inmunofluorescence, migration and invasion 
assays were carried out in order to test anti-migratory and anti-invasive properties of 
compound G2. In addition, the in vivo effect of compound G2 was evaluated in a 
zebrafish model of invasion. HCT-116 cells exhibited the highest Fascin1 expression 
from eight tested colorectal cancer cell lines. Compound G2 showed important 
inhibitory effects on actin bundling, filopodia formation, migration and invasion in 
different cell lines. Moreover, compound G2 treatment resulted in significant reduction 
of invasion of DLD-1 overexpressing Fascin1 and HCT-116 in zebrafish larvae 
xenografts; this effect being less evident in Fascin1 known-down HCT-116 cells. This 
study proves, for the first time, the in vitro and in vivo antitumoral activity of compound 
G2 on colorectal cancer cells and guides to design improved compound G2-based 
Fascin1 inhibitors. 








































































Tumor metastasis remains the leading cause of cancer mortality (Chen, Yang, Jakoncic, 
Zhang, & Huang, 2010). Acquisition of invading capacity is a prerequisite for 
carcinoma cells to get access to vessels and thus spread throughout the body. This 
process involves actin cytoskeleton rearrangement allowing the tumor cells to develop 
cellular protrusions, such as filopodia and lamellipodium, which contribute to cancer 
cell migration, invasion, and metastasis (Machesky & Li, 2010). Fascin1 (FSCN1: 
ENSG00000075618) is a key protein in membrane protrusion, as it possesses actin-
binding and actin-bundling activity by cross-linking filamentous actin into tightly 
packed parallel bundles. Fascin1 expression is often elevated in malignant tumors while 
its expression is low or absent in most normal adult epithelia (Hashimoto, Kim, & 
Adams, 2011).  Fascin1 has emerged as an important biomarker and therapeutic target 
due to its overexpression in several carcinomas and its association with mortality and 
metastasis (Hashimoto et al., 2011; Hashimoto, Skacel, & Adams, 2005). In fact, 
several studies including a meta-analysis have demonstrated that Fascin1 expression is 
associated with increased lymph node- and distant-metastasis, disease progression and 
mortality in both colorectal and breast cancer (Omran & Al Sheeha, 2015; Tan, Lewis, 
Adams, & Martin, 2013). 
In a recent study, our group identified Fascin1 as overexpressed in serrated 
adenocarcinoma (SAC) (Conesa-Zamora et al., 2013), a histological subtype of 
colorectal carcinoma. SAC, in contrast to conventional colorectal carcinoma (García-
Solano, Conesa-Zamora, Trujillo-Santos, et al., 2012), has worse prognosis (García-
Solano et al., 2010) and it is characterized by a more active invasive front evidenced by 
higher occurrence of tumor budding, cytoplasmic pseudofragments, infiltrative tumor 




































































Guillermo, 2011) and E-cadherin loss. Moreover, SACs show a higher frequency of 
KRAS and BRAF mutations than conventional carcinoma which make most of them 
resistant to anti-EGFR therapy (García-Solano, Conesa-Zamora, Carbonell, et al., 2012; 
Stefanius et al., 2011). 
Given the causative role of Fascin1 in the invading phenotype of tumor cells together 
with the association of its overexpression to worse survival of a wide variety of cancer 
types (Cao et al., 2014; Jones et al., 2015; Li et al., 2014; Rodrigues et al., 2017; 
Stewart & Crook, 2015; Zhao et al., 2015) it would be desirable to find efficient 
Fascin1-activity blockers. In this line, migrastatin and its macroketone analogues are 
considered typical Fascin1 inhibitors (Chen et al., 2010). Unfortunately, they are 
difficult to synthesize due to their complex structure (Gaul et al., 2004).  
In this study, we performed a search of patented potential Fascin1 inhibitors, such as 
those derived from indazol-furan-carboxamides (Han et al., 2016). Among them, we 
found the leading compound G2 and showed an inhibitory effect on Fascin1 activity by 
using several in vitro and in vivo assays on well-characterized colorectal cell lines.  
 
Material and Methods 
Compounds and molecular modeling 
Compound G2 (N-(1-(4-(trifluoromethyl) benzyl)-1H-indazol-3-yl) furan-2-
carboxamide; C20H15F3N3O2; PM 386.13) is covered by the patents WO 
2014/031732 A2 and WO 2015/127125A1 and was synthesized as previously described 
(Han et al., 2016). Migrastatin was synthesized by AnalytiCon Discovery (NP-006108) 




































































Autodock Tools (Morris et al., 2009), where partial charges were assigned using 
Gasteiger model (Gasteiger & Marsili, 1980). The structural model for Fascin1 was 
extracted from the crystal structure of protein data bank (PDB) with code 6B0T (Huang 
et al., 2018) and converted to PDBQT format using default parameters. Molecular 
docking calculations based on the Blind Docking (BD) technique (Sánchez-Linares, 
Pérez-Sánchez, Cecilia, & García, 2012) were carried out using Blind Docking server 
(BDS, available at http://bio-hpc.ucam.edu/achilles) with Autodock 4 (Morris et al., 
2009) as docking engine with default parameters. Graphical representations of the 
docking results as PyMOL (http://www.pymol.org) sessions were downloaded from 
BDS with default options as specified on the website.  
All the protocols comply with the recommendation, the approval of which was obtained 
from the participant institutions and in accordance to the ethical standards laid down in 
the 1964 Declaration of Helsinki and its later amendments. 
 
Cell culture 
Distinct human colorectal adenocarcinoma cell lines HCT-116, DLD-1, SW480, HCT-
15, HT-29, LS174T, SW620 and LoVo were obtained from the American Type Culture 
Collection (ATCC, Rockville, MD, USA). Cell lines were cultivated using standard 
high glucose Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
10% heat-inactivated fetal bovine serum (FBS), 50 U/mL penicillin and 50 µg/mL 
streptomycin (all from Sigma Aldrich Chemical Co., USA) at 37 °C and 5% CO2 and 
95% humidified atmosphere. Subculturing was performed when cells reached 90% 
confluence. Cell RNA extraction and qPCR for Fascin1 expression quantification is 




































































genetically overexpressed (DLD-1) and knocked-down (HCT-116) for Fascin-1 
(Supplementary Material S1). 
 
Cell viability assay 
Exponentially growing cells were plated in flat-bottomed 96-well plates (Nunc, 
Roskilde, Denmark) in triplicate (1500 cells/well). Cells were treated with a series of 
concentrations from 500 nM to 100 µM of either migrastatin or compound G2 up to 3 
days (24, 48 and 72 hours) in a 5% CO2 humidified atmosphere. Control cells were 
treated with drug carrier [0.1% dimethyl sulfoxide (DMSO)]. Cells were assayed for 
viability as follows. Briefly, Dulbecco’s phosphate-buffered saline (DPBS) 
supplemented with 1.9 mg/mL tetrazolium (MTT) pH 7.2 was added to the cells (30 
µL/well). After incubation at 37 °C for 4 hours, the medium was carefully aspirated. 
The formazan crystals were dissolved in 200 µL DMSO for 30 min and the absorbance 
was read in a microtiter plate reader at 570 nm and 620 nm as reference. Results were 
calculated as: cell viability (%) = average optical density (O.D.) of wells/average O.D. 
of control wells. 
 
Cell Migration Assay 
Cell migration was studied using HCT-116 and DLD-1 cell lines by performing a 
scratch wound healing assay in standard medium supplemented with 5% FBS. 
Typically, 50,000 cells were plated in low 35-mm-dishes with culture inserts following 
manufacturer instructions (Ibidi, Martinsried, Germany). After appropriate cell 




































































sterile forceps to create a wound field of approximately 500 µm. Detached cells were 
gently removed with DPBS before the addition of drugs. Confluent cells were incubated 
in one of the following treatments: control (0.1% DMSO), 100 µM migrastatin, 5, 10 
and 20 µM compound G2. Cells were then placed in a cell culture incubator and they 
were allowed to migrate. At 0, 4 and 7 hours (linear growth phase), 10 fields of the 
injury area were photographed with an inverted phase contrast microscope using 10X 
magnification. For each time point, the area uncovered by cells was determined by 
Image J software (National Institute of Health, Bethesda, MD, USA). Each treatment 
was performed in triplicate. 
The migration speed of the wound closure was given as the percentage of the recovered 
area at each time point, relative to the initially covered area (t0). The velocity of wound 
closure (%/h) was calculated according to the formula:  
Slope (%/h) =
(% covered area 𝑡𝑥) − (% covered area 𝑡𝑜)
(𝑡𝑥 − 𝑡𝑜)
 
Slopes are expressed as percentages relative to control conditions. 
 
Transwell invasion assay  
The invasive capacity of HCT-116 cells was determined using Cytoselect TM 24 Well 
Cell Invasion Assay (Basement Membrane Colorimetric Format) with MatrigelR coated 
Transwell chambers (8 μm pore size) (Cell Biolabs Inc., CA, USA). Briefly, cells 
(9.5×104) were resuspended in serum-free medium with corresponding inhibitors (100 
µM migrastatin and 20 µM compound G2) and seeded into the upper chamber. 
Additionally, 500 μL of standard medium were added to the well. After 30 hours of 




































































swab, and the cells that had migrated through the matrigel and reached the bottom of the 
chamber were stained with the cell stain solution provided in the kit. Invasiveness was 
quantified by counting cells on the lower surface of the filter using Image J software 
(National Institute of Health, Bethesda, MD, USA). In addition, invasive cells at the 
bottom side of the filter were eluted and quantified at an absorbance of 560 nm. 
 
Myoma organotypic invasion model 
Tumoral cell invasion was assessed in the myoma organotypic cultures and performed 
according to the previously published myoma model protocol (Nurmenniemi et al., 
2009; Åström, Heljasvaara, Nyberg, Al-Samadi, & Salo, 2018). Briefly, uterine 
leiomyoma tissues were obtained from routine surgery after informed consent of the 
donors and their use approved by The Ethics Committee of the Oulu University 
Hospital. The myoma tissue was sliced into 5 mm and disks were made with an 8-mm 
biopsy punch (Kai Industries Co., Gifu, Japan). Myoma disks were pre-incubated in 
either 0.1% DMSO, 100 μM migrastatin, 10 µM and 20 µM compound G2 at 4 °C for 
48 hours. The myoma disks were placed into Transwell inserts (diameter 6.5 mm; 
Corning Incorporated, Corning, NY) and 700,000 cells in 50 μL of media were added 
on top of each myoma disk. Cells were allowed to attach overnight and the myoma 
disks, transferred onto uncoated nylon disks and be treated with the compounds for 14 
days, while changing the treatment media every 3 days. Subsequently the myoma discs 
were fixed with 4% neutral buffered formalin for 24 hours and 6 μm sections were cut 
and stained with cytokeratin AE1/AE3 (M3515, Dako). Sections were documented at 
10X magnifications, using the Leica DMRB microscope DFC 480 camera with the 




































































(National Institute of Health, Bethesda, MD, USA) was used to measure invasion areas 
and depths. Each treatment was performed in triplicate.  
 
Zebrafish invasion assays and treatments 
The colonization of zebrafish (ZF) (Danio rerio) embryos by human cancer colorectal 
cells lines was performed as previously described (Jelassi et al., 2011). The experiments 
performed comply with the Guidelines of the European Union Council (Directive 
2010/63/EU) and the Spanish RD 53/2013. Experiments and procedures were 
performed as approved by the Bioethical Committee of the Murcia University (Spain). 
Briefly, human cell lines were trypsinized, washed and stained with fluorescent CM-Dil 
(Vibrant, Invitrogen) following manufacturer´s instructions. Fifty to 100 labelled cells 
were injected into the yolk sac of dechorionated ZF embryos and transferred into 24 
well plates. Fish with fluorescently labelled cells appearing outside the implantation 
area at 2 hours post-injection (dpi) were excluded from further analysis. All other fishes 
were treated, by bath immersion, with E3 medium (5 mM NaCl, 0.33 mM KCl, 0.33 
mM CaCl2, 0.33 mM MgSO4, 0.1% methylene blue) (all from Sigma-Aldrich, St Louis, 
MO, USA) supplemented with either 100 µM migrastatin or 5-10 µM compound G2 for 
96 hours at 35 ºC. Treatment was renewed every 24 hours. Larvae analyzed with a 
M205-FA stereomicroscope equipped with a DFC365FX camera (Leica). The 
evaluation criteria for embryos being colonized by human cancer cells was the presence 
of more than three cells outside of the yolk sac and, with this criterion, ZF percentage of 
invasion was calculated.  
With the aim of finding out whether the pro-metastatic activity of Fascin1-induced 




































































Zebrafish embryos xenografted with Fascin1-transfected DLD-1 cells were incubated 
up to 144 hours. The day of invasion screening (fourth day post xenograft), freshly 
prepared E3 medium was supplemented with 100 µM migrastatin or 10 µM compound 
G2 together with 375 rotifers/mL (Brachionus plicatilis (L-type); ReefNutrition, 
Campbell, CA, USA). The number of small colonies generated from individual 
invading cells was counted on the sixth day post xenograft (6 dpi). This was considered 
as the number of ZF larvae with metastasis.  
 
Data analysis 
Data are expressed as mean ± standard deviation (SD). Data were analyzed for 
statistical differences by the Student’s t-test for paired and unpaired data after testing for 
normal distribution of the data. For in vitro experiments, one-way analysis of variance 
(ANOVA) was performed followed by a Tukey poshoc test to compare each group. 
Differences were considered significant at an error probability of P < 0.05. SPSS 18.0 
software was used for the rest of statistical analyses (SPSS, Inc, Chicago, Illinois, 
USA). For myoma assay OriginPro 2016 software was used for statistical calculations. 
One-way ANOVA (analysis of variance) with post-hoc comparisons based on the 
Tukey's multiple comparisons test were applied. The level of significance considered 
was 5% (p≤0.05). 
 
Results 
Molecular Modeling  
Figure 1 shows the main resulting pose of compound G2 after blind docking 




































































interactions established are related to hydrogen bonds (GLU215), pi-pi (TRP101) and 
hydrophobic interactions (LEU16, PHE14, LEU48, ILE93, VAL134, GLU215, 
PHE216). It must be noticed that these residues participate in the actin-binding site 2, 
located within the pocket formed by β-trefoil 1 and 2 from the Fascin1 structure, and 
that blind docking calculations were able to predict this interaction spot with no 
previous assumption about binding site. In addition, this prediction coincides rather well 
with crystallographic pose of ligand compound G2-029 (PDB: 6B0T), which is to be 
expected due to the small difference between compound G2 and G2-029 molecules, just 
a methyl group. 
 
Compound G2 prevents in vitro Fascin1-induced F-actin bundling  
In order to assess the effect of compound G2 on Fascin1, we performed an F-actin 
bundling assay under transmission electron microscopy (TEM) (Supplementary material 
S1). As shown in Figure 2, only F-actin incubated in the presence of untreated Fascin1 
formed filament bundles (12.00 [9.00-19.75]). Fascin1 preincubated with 100 μM 
migrastatin or compound G2 (up to 20 μM) lead to the disorganization of the bundles, 
resulting in fewer filaments than in control conditions (Kruskal-Wallis test, p<0.001). 
No statistically changes were found between the different drug treatments (Kruskal-
Wallis test, p=0.370). 
 





































































In order to choose colorectal cell lines with highest and lowest endogenous Fascin1 
expression, a RT-qPCR was performed upon RNA extracted from eight cell lines. As 
shown in Supplementary Material 2,  HCT-116 and SW480 exhibited the highest 
Fascin1 expression whilst LoVo, DLD-1 and HT-29 had the lowest. Given the ease for 
cell culture and the differences in endogenous Fascin1 expression, we selected DLD-1 
(low Fascin1 expression) and HCT-116 (high Fascin1 expression) cell lines in 
subsequent assays. 
To assess the Fascin1 inhibition activity of the compound G2 on cell viability, we tested 
different concentration of migrastatin and compound G2 on different colorectal cancer 
cells. As shown Supplementary Material S3, migrastatin was generally better tolerated 
than compound G2 by the DLD-1 and HCT-116 cell lines. Thus, the working 
concentrations for migrastatin and compound G2 were set up for subsequent in vitro 
studies at 100 µM and up to 20 µM, respectively. 
 
The effect of compound G2 on Fascin1 localization and the reorganization of the actin 
cytoskeleton as well as on the protrusion of lamellipodium at the cell front was assessed 
by immunofluorescence. For that purpose, we used HCT-116, the colorectal cell line 
with maximum expression levels of Fascin1 together with Fascin1 silenced HCT-116 
cells. As shown in Figure 3, prominent lamellipodium formation was observed in 
control conditions and for EGF treated cells (non-significant differences between each 
other were found). However, these cytoskeleton structures were absent in cells treated 
with migrastatin and compound G2, similarly to what it was observed with PD98059, an 
inhibitor targeting the MEK pathway. Lamellipodium protrusion numbers calculated at 
different conditions were significantly lower upon both migrastatin and compound G2 




































































showed that the treatments also abolished the actin bundles in lamellipodium. Similar 
results were observed with an extra cell line expressing Fascin1 (HaCat) as DLD1 
morphology was not suitable for assessing lamellipodium formation (data not shown).  
Transcriptional Fascin1 silencing of HCT-116 abolished the Fascin1 accumulation at 
lamellipodium sites and produced an alteration of F-actin microfilament assembly in 
silenced cells (Supplemental S5D).  
 
Compound G2 diminishes migration and inhibits Matrigel cell invasion of colorectal 
cancer cells 
In order to correlate the observed effect of Fascin1 inhibitors on lamellipodium 
protrusion to an effect on cell migration, migrastatin and compound G2 treated cells 
were investigated for their migration activity using an in vitro wound healing scratch 
assay. As shown in Figure 4, compound G2 produces a remarkable inhibition of 
migration in HCT-116 and DLD-1 cell lines (p<0.01). Compound G2 effect at 20 μM 
was more pronounced than migrastatin in DLD-1 cells, whist in HCT-116 the effect of 
compound G2 on migration was lower.  
Tumor cell invasion not only involves the acquisition of migration properties but also 
the ability to degrade the basement membrane and tumor stoma matrices, three-
dimensional substrates (Albini, 1998).For that reason, we performed a Transwell assay 
on MatrigelR which resembles the basement membrane extracellular matrix 
composition. As shown in Supplementary material S6, both compound G2 and 
migrastatin inhibit tumor cell invasion of HCT-116, the effect of the latter being slightly 
more evident. 
 To further confirm the inhibitory effect of compound G2 on the Fascin1 activity, we 




































































migration and invasion properties. Fascin1 silencing produces a slight decrease of 
migration and invasion compared to MOCK HCT-116 cells (p<0.05), whereas double 
inhibition (genetic and pharmacological) only produced a significant decrease in 
migration (Supplemental material S7A-B). Accordingly, 10 µM compound G2 strongly 
diminished migration and invasion in Fascin1 overexpressed DLD-1 cells (p<0.01) 
(Supplemental material S7C-D). 
 
Compound G2 diminishes HCT-116 colon cancer cells invasion in a human benign 
leiomyoma tissue in vitro 3D model  
In order to find out whether the anti-invasive properties of compound G2 on cancer cell 
invasion could be translated into a 3D human model, a myoma disc organotypic model 
was used. As shown in Figure 5, compound G2 (5 µM) significantly reduced the 
invasion depth and invasion area of HCT-116 cells into the discs when compared to 
untreated cells (P<0.01). Similar results were obtained when cells were treated with 10 
and 20 µM compound G2 (Supplementary material S8). 
  
Compound G2 inhibits the invasive capacity of HCT-116 tumor cells in an in vivo assay 
of zebrafish model 
In order to find out whether the anti-invasive properties of compound G2 could be 
extrapolated to a living animal, a xenograft assay was carried by using the well-
established zebrafish (ZF)-larvae invasion model. To test viability, groups of thirty 
larvae were treated with either 100 µM migrastatin or 5, 10 and 20 µM compound G2. 
The majority of larvae were viable after three days treatment with either 5 or 10 µM.  
However, 20 µM compound G2 treatment caused larvae death at the third day of 




































































assays were 5 and 10 µM compound G2. Later on, detached and labelled colorectal 
cancer cells were injected into the yolk sac and colonization was followed up to 6 days. 
The percentage of invasion was studied for four colorectal cancer cell lines (Fig. 6A and 
6B) that exhibited different Fascin1 expression levels (Supplementary material S2). 
HCT-116 and DLD-1 were selected for being the cell lines with the highest and lower 
Fascin1 expression, respectively. Good correlation was observed between Fascin1 
expression and cell invasion for all cell lines assayed except HCT-15 whose invasion 
was lower than expected (Figure 6B)  possibly due to other fascin1 independent factors 
affecting invasion  (Stevenson, Veltman, & Machesky, 2012). Therefore, and because of 
good correlation, HCT-116 was selected for being the cell line with the highest and 
DLD-1 for its lower Fascin1 expression and cell invasion. To further test the in vivo 
involvement of Fascin1 in this phenomenon, we performed exogenous silencing of 
Fascin1 in HCT-116 cells (Figure 7A). Either genetic reduction of Fascin1 or its 
pharmacological inhibition by compound G2 decreased the invasion in HCT-116 cells 
(Figures 7B and 7C). Conversely, we induced the over-expression of Fascin1 by means 
of plasmid transfection into DLD-1 cells (Figure 7D), thus correlating with a higher 
invasion capacity (Figure 7E). Compound G2 kept inhibiting invasion in both, MOCK 
and transfected Fascin1-overexpressing cells (Figure 7F). Consequently, in vivo 
invasion correlated with Fascin1 expression and compound G2 inhibited it in 
transfected cells (Figures 7E and 7F).  Furthermore, a clear increase of the number of 
ZF larvae with metastasis was observed with Fascin1-overexpressing DLD-1 cells 
although 10 µM compound G2 treatment had a similar effect on ZF groups subjected to 






































































Colorectal serrated adenocarcinoma and triple negative breast carcinoma are 
characterized by their bad prognosis, over-expression of Fascin1 and the absence of 
targeted molecular therapy (Conesa-Zamora et al., 2013; Esnakula et al., 2014; García-
Solano, Conesa-Zamora, Carbonell, et al., 2012; García-Solano et al., 2016; Ghebeh et 
al., 2014; Kanda et al., 2014; Rodríguez-Pinilla et al., 2006; Stefanius et al., 2011; 
Wang et al., 2016). Han et al. demonstrated an inhibitory effect of compound G2 and its 
derivates on Fascin1-driven actin bundling. Moreover, they showed an anti-migratory 
and anti-invasive effect of compound G2 on breast cancer cells (Han et al., 2016). In the 
present report we include a molecular model, which provided an improved 
understanding regarding atomic details of the interactions between compound G2 
chemical class and Fascin1 inhibition and will guide the future identification of more 
potent anti-metastatic drugs. Using blind docking calculations, the model identified a 
region in Fascin1 possibly involved in compound G2 binding. Some prior evidences 
support this finding as this region is part of the actin binding site 1, as described by Han 
et al. (Han et al., 2016). In accordance, preincubation of Fascin1 with migrastatin and 
compound G2 disrupted the F-actin bundle formation in vitro. Herein, among the 
different colorectal cell lines used in this study, HCT-116 expressed the highest Fascin1 
levels and its migration capacity was clearly reduced after treatment with compound 
G2, even at lower concentrations than migrastatin and in a dose-dependent manner. 
Invasion and confocal studies were further performed with HCT-116 cells because of its 
morphological features and higher Fascin1 expression levels. We showed that both 
inhibitors, migrastatin and compound G2, strongly abolished the protrusion of 
lamellipodium, as confirmed by rescue experiments in Fascin1 silenced cells. 
Furthermore, we observed similar inhibitory effects of migrastatin and compound G2 on 




































































Myoma discs represent a superior 3D model for cancer cell invasion studies compared 
to the other, non-human tissue based, organotypic models (Salo et al., 2018). In myoma 
assay, both migrastatin and compound G2 were similarly able to significantly decrease 
both the invasion depth and invasion area of HCT-116 cells. It is important to notice 
that cell death caused by long-time incubation with the compound G2 was avoided in 
the migration and invasion in vitro assays, since viability did not seem to be 
compromised after 30 hours. Of note, no previous studies have analyzed the effect of 
migrastatin or compound G2 on human solid, hypoxic, myoma disc organotypic 
invasion assay. 
Moreover, in vivo assays using a model of ZF where Fascin1 expression was modified 
in colorectal cells showed that compound G2 effects on colorectal cancer cells invasion 
capacities showed a Fascin1 dependency. This compound inhibits the invasion of two 
cell lines of colorectal cancer with high expression of Fascin1, both constitutive and 
induced, without affecting the ZF viability and with a more pronounced effect than 
migrastatin. This activity also had an effect on colony formation from individual 
invading cells thus suggesting an inhibition of both invasion and metastasis of Fascin1-
tranfected tumor cells. It is worth of mentioning that this validated model was capable 
of testing a very high number of individuals per assay. However and despite these 
evidences, additional off-target anti-tumoral effects of G2 apart from Fascin1 are also 
possible. 
In conclusion, this study reports a Fascin1 inhibitor with anti-migratory and anti-
invasive properties in colorectal cancer cells at lower concentrations than migrastatin, 
the typical Fascin1 inhibitor. Using this strategy, we have here confirmed a novel class 




































































tumoral cells, such as SAC; providing the first rationale for a tailored therapy in this 
type of cancer.  
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Table 1. Lamellipodium protrusion numbers in the different conditions in HCT-116 
cells. 
 Control 100 µM 
migrastatin 
20 µM 







9 ± 1.5 2 ± 2 5.8 ± 1.1 10.4 ± 1.5 1 ± 1 
P value*  0,000139 0,002936 0,140178 5,9241E-06 


















































































Figure 1. Main interactions obtained after blind docking of compound G2 against 
Fascin1. Blue solid line represents hydrogen bond, green dashed line aromatic 
interactions, and dashed grey lines hydrophobic interactions. Inset: compound G2 
chemical structure. 
Figure 2. Transmission electronic microscopy visualization of actin binding and 
bundling activities of Fascin1 treated or not with inhibitors (negative staining). A) 
Stained F-actin filaments alone. B) F-actin bundling assay with filamentous F-actin and 
untreated Fascin1 (1:1 molecular ratio) (control condition). C) F-actin bundling assay 
with filamentous F-actin and Fascin1 previously incubated with 100 μM migrastatin 
(1:1 molecular ratio). D) F-actin bundling assay with filamentous F-actin and Fascin1 
previously incubated with 20 μM compound G2. Magnification: A 120.000X and B to 
D 93.000X. E) Quantitative analysis of the numbers of actin filaments bundles in the 
stated conditions (*** p<0.001 compared to control condition), non-significant (N.S.) 
between treatments (Kruskal-Wallis test).  
Figure 3. Migrastatin and compound G2 affect lamellipodium formation and 
morphology of HCT-116. Representative images of immunofluorescence assays for 
Fascin1 (lower inset in detail) are shown. A) Control condition; B) 100 µM migrastatin; 
C) 20 µM compound G2; D) 50 µM PD98059 (Mek inhibitor); E) 10 ng/mL Epidermal 
Growth Factor (EGF, migration stimulator). Cells were fixed and stained with anti-
Fascin1 antibody (1/250). Images were captured with a LSM 510 META confocal 
fluorescence microscope with 63X oil objective. Fascin1 location is show in green in 




































































migrastatin and compound G2 inhibited lamellipodium protrusion and Fascin1 
localization in a similar way to the migration Mek inhibitor. 
Figure 4. Migrastatin and compound G2 prevent cell migration on HCT-116 and DLD-
1 colorectal cancer cells. A) Effect of 100 µM migrastatin and 20 µM compound G2 on 
HCT-116 and B) DLD-1 cells. C) Percentage of migration for 100 µM migrastatin and 
compound G2 (5, 10, 20 µM) treatments. Migration was calculated with respect to the 
control conditions (100%) for a slope between 4 and 7 hours (lineal phase). ** p<0.01. 
Figure 5. Myoma organotypic invasion model in HCT-116 cell line. A)  Invasion of the 
cells within myoma discs after treatment in control conditions, B) 100 µM migrastatin, 
and C) 5 µM compound G2. Pictures were taken under a phase contrast microscope 
with 100X magnification and 100 µm scale bars. D) The invasion area and E) Invasion 
depth of cytokeratin positive cells were quantified with image J.  Data is shown as mean 
± SD compared with the control. ***p<0.001.  
Figure 6. Zebrafish invasion assays. A) Zebrafish invasion model. Representative 
images of a zebrafish embryo with no invasion where the labeled cells remained in the 
yolk and never invaded the embryo and an embryo with invasion where the cells were 
able to migrate outside of the yolk. Magnification of the tail region of an embryo with 
invasion is shown at the right. B) Invasiveness of each cell line in this model. Data is 
shown as mean ± SD; compared with the control. * p=0,049-0, 01; ** p=0,001-0,009. 
Figure 7. Treatment effects on cancer cell invasion with different grades of Fascin1 
expression. A) Inhibition of Fascin1 gene expression upon siRNA-Fascin1 transfection 
in HCT-116 cells. B) Effect of 5 and 10 µM compound G2 on HCT-116 invasion with 
endogenous and silenced Fascin1 expression. C) Compound G2 inhibitory activity on 




































































difference between percentage of invasion in control (MOCK) and percentage of 
invasion in treated cells. Second two columns represent the difference between 
percentage of invasion in siRNA Fascin1-transfected HCT-116 and percentage of 
invasion in compound G2-treated siRNA Fascin1-transfected HCT-116 cells. Note that 
the effect of compound G2 decreased when Fascin1 was silenced. D) Overexpression of 
Fascin1 gene upon Fascin1 transfection in DLD-1. E) Effect of 5 and 10 µM compound 
G2 on DLD-1 invasion with endogenous and exogenous Fascin1 expression. F) 
Compound G2 inhibitory activity on control and Fascin1-transfected DLD-1 cells. First 
two columns represent the difference between percentage of invasion in control 
(MOCK) and percentage of invasion in treated cells. Second two columns represent the 
difference between percentage of invasion in Fascin1-transfected DLD-1 and 
percentage of invasion in compound G2-treated Fascin1-transfected DLD-1. Note that 
the effect of compound G2 increased when Fascin1 was overexpressed by transfection. 
Data is shown as mean ± SD; compared with the control, *p= 0,049-0, 01. ** p=0,001-
0,009. *** p= 0, 0001-0, 0009. **** p<0, 0001. 
 
Supplementary material 
Supplementary material S1. Detailed description of experimental protocols. 
Supplementary material S2. Fascin1 gene expression in colorectal cell lines. mRNA 
expression levels of Fascin1 was quantified in eight colorectal cell lines using a β-actin 
gene expression for data normalizing.  
Supplemental material S3. Colorectal cell line viability assay. The effect of 
migrastatin and compound G2 concentrations in HCT-116 and DLD-1 cell lines is 




































































Supplementary material S4. Representative images of immunofluorescence assays for 
actin are shown in HCT-116 cells. A) Control condition; B) 100 µM migrastatin; C) 20 
µM compound G2; D) 50 µM PD98059 (Mek inhibitor); E) 10 ng/mL Epidermal 
Growth Factor (EGF, migration stimulator). For actin staining, cells were fixed and 
stained with anti-actin antibody (1/1000). Images were captured with a LSM 510 
META confocal fluorescence microscope with 63X oil objective. Actin filaments are 
show in red in these structures. Co-staining with Hoechst-33258 was used to show the 
cell nuclei. Lamellipodium are more prominent in control and EGF conditions.  
Supplementary material S5. Representative images of immunofluorescence assays for 
fascin1 (green), nucleus (blue) and actin (red) are shown. A) Control condition (DMSO) 
with siRNA-A transfected HCT-116 cells; B) Control condition (DMSO) with fascin1 
silenced HCT-116 cells; C) Fascin1 silenced HCT-116 cells with 10 ng/mL Epidermal 
Growth Factor (EGF, migration stimulator), D) Fascin1 silenced HCT-116 cells with 50 
µM PD98059 (Mek inhibitor). Colorectal carcinoma HCT-116 cells were genetically 
knocked-down for Fascin1 with short interfering siRNA, control HCT-116 was 
transfected with siRNA-A (MOCK). Cells were fixed with bouin and co-stained with 
anti-Fascin1 antibody (1/250) and Hoechst-33258. For actin staining, cells were fixed 
with methanol and stained with anti-actin antibody (1/1000). Images were captured with 
a LSM 510 META confocal fluorescence microscope with 63X oil objective.  
Supplementary material S6. Transwell invasion assay in HCT-116 cell line. A) 
Invasiveness of cells after treatment in control conditions, 100 µM migrastatin and 20 
µM compound G2, respectively. Pictures were taken under an inverted phase contrast 
microscope. The magnification was 200X and scale bars =50 μm. B) Quantification of 




































































cells using the Image J software. Data is shown as mean ± SD; compared with the 
control. **p<0.01. 
Supplementary material S7. Inhibition of the migration and invasive capacities by 
compound G2 in transfected cells. A) Percentage of migration. B) Percentage of 
invasion. Colorectal carcinoma HCT-116 cells were genetically knocked-down for 
Fascin1 with short interfering siRNA, MOCK control HCT-116 was transfected with 
siRNA-A. Colorectal carcinoma DLD-1 cells were genetically overexpressed for 
Fascin1 with Fascin1-GFP vector, MOCK control DLD-1 was transfected with pGFP 
N3 control vector. Data are representative of two similar experiments Error bars, mean 
± SD of duplicates. * p<0.05, ** p<0.01 compared to MOCK condition; n.s: non-
significant. 
Supplementary material S8. Myoma organotypic invasion model in HCT-116 cell 
line. A)  Invasion of the cells within myoma discs after treatment in A) control 
conditions; B) 100 µM migrastatin; C) 20 compound G2 and D) 10 µM compound G2. 
Pictures were taken under a phase contrast microscope with 100X magnification and 
100 µm scale bars. E) Invasion area and F) Invasion depth of cytokeratin positive cells 
were quantified with image J.  Data is shown as mean ± SD compared with the control. 
** p<0.01 ***p<0.001. 
Supplementary material S9. Viability of treated zebrafish larvae in the E3 medium. A) 
Non injected larvae. B) Additionally, larvae (>20 per condition) were injected with 
HCT-116 and treatments were added to the E3 medium. C) Larvae were injected with 
transfected DLD-1 tumoral cell lines and treated. 
Supplementary material S10. Metastasis potential. The number of colonies generated 




































































transfected and Fascin1-tranfected DLD-1 cells showed a decrease in the number of 
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